Principal stratification used to play a role only in observational research but at least since the addendum of the ICH E9 guideline, this approach to causal inference became a hot topic.

In this episode, I talk with 2 experts from Novartis and Roche. We cover the following questions:

  • What is Principal Stratification?
  • How would you describe principal stratification to a non-statistician?
  • Where do you see the benefits of this estimand compared to the other typical strategies?
  • Which critique points do are usually raised against this approach?
  • How do you implement/calculate corresponding estimates for this estimand?
  • What references would you recommend for further reading?

Never miss an episode!

Join thousends of your peers and subscribe to get our latest updates by email!

Get the shownotes of our podcast episodes plus tips and tricks to increase your impact at work to boost your career!

We won’t send you spam. Unsubscribe at any time. Powered by ConvertKit

Learn on demand

Click on the button to see our Teachble Inc. cources.

Load content

Kaspar Rufibach

Kaspar is an Expert Statistical Scientist in Roche’s Methods, Collaboration, and Outreach group and located in Basel.

He does methodological research, provides consulting to Roche statisticians and broader project teams, gives biostatistics trainings for statisticians and non-statisticians in- and externally, mentors students, and interacts with external partners in industry, regulatory agencies, and the academic community in various working groups and collaborations.

He has co-founded and co-leads the European special interest group “Estimands in oncology” (sponsored by PSI and EFSPI, which also has the status as an ASA scientific working group, a subsection of the ASA biopharmaceutical section) that currently has 39 members representing 23 companies, 3 continents, and several Health Authorities. The group works on various topics around estimands in oncology.

Kaspar’s research interests are methods to optimize study designs, advanced survival analysis, probability of success, estimands and causal inference, estimation of treatment effects in subgroups, and general nonparametric statistics. Before joining Roche, Kaspar received training and worked as a statistician at the Universities of Bern, Stanford, and Zurich.

More on the oncology estimand WG:
More on Kaspar:

Björn Bornkamp

Statistical Methodologist at Novartis

Björn Bornkamp works in the Statistical Methodology Group at Novartis in Basel, where he provides consulting to statisticians and clinical teams on topics related to dose-finding studies, subgroup analyses, Bayesian statistics as well as estimands and causal inference.

Join The Effective Statistician LinkedIn group

I want to help the community of statisticians, data scientists, programmers and other quantitative scientists to be more influential, innovative, and effective. I believe that as a community we can help our research, our regulatory and payer systems, and ultimately physicians and patients take better decisions based on better evidence.

I work to achieve a future in which everyone can access the right evidence in the right format at the right time to make sound decisions.

When my kids are sick, I want to have good evidence to discuss with the physician about the different therapy choices.

When my mother is sick, I want her to understand the evidence and being able to understand it.

When I get sick, I want to find evidence that I can trust and that helps me to have meaningful discussions with my healthcare professionals.

I want to live in a world, where the media reports correctly about medical evidence and in which society distinguishes between fake evidence and real evidence.

Let’s work together to achieve this.